Gene therapy for arthritis – where do we stand?

doi:10.1186/ar1823

Arthritis Research & Therapy

Volume 7
Issue 6

Viewing options:

Abstract
Full text
PDF (40KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Chernajovsky Y

on PubMed

Chernajovsky Y
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Commentary

Gene therapy for arthritis – where do we stand?

Yuti Chernajovsky

Bone and Joint Research Unit, William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London, London, UK

author email corresponding author email

Arthritis Research & Therapy 2005, 7:227-229doi:10.1186/ar1823


Published:	14 September 2005

Abstract

The successful use of biologicals in the treatment of rheumatoid arthritis, psoriatic arthritis and spondyloarthritis has had a major impact on the management of these conditions. The challenge in the development of gene therapy as an alternative to these current treatments is to demonstrate that such therapy is more advantageous for patients from the therapeutic and safety points of view. Also, it will need to be demonstrated that gene therapy for the arthritides is economically feasible and that patient populations worldwide will be able to access these treatments.